Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Gilead will donate vials of its antifungal medication AmBisome to help global efforts in eliminating visceral leishmaniasis.
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic…
Eli Lilly has made a six-year, $50 m | Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to…
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million)…
Gilead teams up with WHO again to eliminate parasitic tropical disease - Pharmaceutical Technology
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Ibrance's would-be successors, the data that helped sell Tubulis to Gilead, and more at ASCO
Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M
Gilead Sciences acquires Tubulis for $5bn
Immunovant shares surge on arthritis trial data
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
New data show VEGF bispecifics could compete with Summit, Akeso drug
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
